German Chancellor Olaf Scholz emphasizes significance for Germany as research location at cornerstone laying ceremony Research center to accelerate biop...
Under Narasimhan's leadership, the company sees significant sales and profit growth across major products, prompting an upward revision of the full-year 20...
Johnson & Johnson announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to...
EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced th...
Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have officially announced a definitive agreement for Genmab's acquisition of ProfoundBio in an all-cash dea...
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...
AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a trailblazing clinical-stage biopharmaceutical company speciali...
The deal, valued at up to $1.05 billion, comprises an $800 million upfront payment and an additional $250 million contingent upon r...
– Proceeds will be used to complete clinical demonstration trials of the lead candidate drug RNDP-001 for the treatment of Parkinson's di...
Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...
Aizon, the AI SaaS provider transforming pharmaceutical manufacturing, announced today the closing of a $20 million...
In a move that adds an intriguing layer to the IPO dynamics, Alto has granted underwriters a 30-day option to scoop up an additional 1,206,000 shares of co...
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin of 29.8% Continued growth inves...
Pfizer does not endorse TRC Capital Investment’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in respons...
© 2024 Biopharma Boardroom. All Rights Reserved.
